Get Ready for Hep C Meds Maviret and Vosevi

October 2017

You'll see big changes in treating hepatitis C due to the new oral antivirals, Maviret and Vosevi.

Maviret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.

It'll also be the lowest priced option at about $43,000/course...compared to $68,000 for Harvoni or $61,000 for Epclusa for 12 weeks.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Pediatrics Suggest Lifestyle Changes First for Most Hypertensive Kids
Contraceptives Help Women Stay on Schedule With Their Hormonal Contraceptives
Stroke Some Patients May Switch Antiplatelets if They Have a Stroke on Aspirin
Psychiatry Recommend Psychotherapy Before Meds for Post-Traumatic Stress Disorder (PTSD)
Smoking Cessation Think of Cravv (cytisine) as Similar to Champix for Smoking Cessation
Infectious Diseases Recommend Gentamicin if a Cephalosporin Is Not an Option for Gonorrhea
Bowel Preps Help Patients With Bowel Preps for Colorectal Cancer Screening
Hair Loss Explain What Works and Doesn't Work for Hair Loss in Women
Explain Treatment Pros and Cons With Simple Statistical Terms
Hepatitis C Get Ready for Hep C Meds Maviret and Vosevi
Practice Get Our CE to Be Ready for the Next Disaster
Practice Use These Strategies to Pass Inspections With Flying Colours

Get Ready for Hep C Meds Maviret and Vosevi

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents